Building Blocks

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>3-Chloropyrazin-2(1H)-one is an organic compound with the molecular formula C6H5ClO. It is a colorless liquid that spontaneously polymerizes. 3-Chloropyrazin-2(1H)-one has been shown to have a number of functions, including reactions with cyclohexanone and acetone to produce ethyl formate, as well as reactions with acetonitrile and ethyl formate to produce 2-ethoxyethyl acetate. Phase equilibrium data for 3-chloropyrazin-2(1H)-one are given in terms of the liquid and vapor phases at various pressures and temperatures. The solvents used in crystallographic studies of 3-chloropyrazin-2(1H)-one include tetrahydrofuran (THF) and dimethyl sulfoxide (DMSO). Experimental data for 3-chloropyrazin-2(1H)-one is</p>

<p>Versatile small molecule scaffold</p>

Versatile small molecule scaffold

<p>2-Bromo-5-ethynylthiophene is a terminal alkyne that can be used as a ligand, an additive, or as an intermediate in organic synthesis. 2-Bromo-5-ethynylthiophene can be obtained by heating ethynylacetylene with bromine and sulfuric acid. It is insoluble in water and other solvents, and has two different conformations. The two isomers are distinguished by their reaction time to form the diacetate monomer. The diacetate monomer reacts more quickly than the monoacetate monomer because it has a higher energy barrier. 2-Bromo-5-ethynylthiophene can also be used in devices such as OLEDs and solar cells.</p>

<p>(4-Bromophenyl)methyl 2-hydroxybenzoate is a natural product of plant origin. It is an analytical standard for HPLC, and is used as a reference material in the analysis of secondary metabolites and natural products. (4-Bromophenyl)methyl 2-hydroxybenzoate has been isolated from "Paeonia suffruticosa".</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>This chemical is an inhibitor of protein interactions. It has been used as a research tool and as a pharmacological agent. This product is a ligand that binds to receptors or ion channels, which are proteins found in the cell membrane or cell wall. When these proteins interact with ligands, they can initiate a response inside the cell, such as opening or closing ion channels or initiating other cellular processes. The efficacy of this product depends on its concentration and binding affinity for the receptor or ion channel. This product has been shown to inhibit the activity of both potassium and calcium channels at high concentrations.</p>

<p>Versatile small molecule scaffold</p>

<p>Please enquire for more information about 5-Fluoropyridine-2-boronic acid including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>2-fluoro-4-iodobenzonitrile is a potent inhibitor of the functions of VEGFR receptors. It inhibits the proliferation and migration of cancer cells by binding to VEGFR receptors, which are tyrosine kinases that regulate cell growth and differentiation. 2-Fluoro-4-iodobenzonitrile has been shown to inhibit angiogenesis, or the formation of new blood vessels, in vitro. This drug also has potent inhibitory activity against tumor growth in vivo. Clinical trials have shown that 2-fluoro-4-iodobenzonitrile can be used to treat various types of cancers, including breast cancer and colon cancer.</p>

<p>Please enquire for more information about 3-Fluoro-N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-alanine including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>BI 2536 is a protein kinase inhibitor that specifically blocks the activity of the protein Bcl-2-interacting killer (BIK) by binding to its ATP-binding site. It has been shown to induce apoptosis in cancer cells, including squamous cell carcinoma and HL60 cells. BI 2536 inhibits tumor growth in mice with solid tumours, such as sarcomas and carcinomas, by inducing autophagy. This drug also has an anti-inflammatory effect against mouse tumors through Toll-like receptor 9 activation. BI 2536 induces programmed cell death in cancer tissues by inhibiting the expression of the Mcl-1 protein.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

Versatile small molecule scaffold

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>JMS-17-2 is a small molecule that was shown to have a potent and selective inhibitory effect on the production of chemokines in cancer cells. It blocks the interaction between CXCL12 and its receptor, CXCR4. This interaction is important for normal bone tissue development and function, as well as for chemotaxis and metastasis of cancer cells. JMS-17-2 has been shown to prevent tumor growth in animal models by inhibiting angiogenesis, or the formation of new blood vessels to supply nutrients to tumors. The drug also inhibits tumor growth by decreasing the number of primary tumors, reducing bone lesions, and inhibiting the progression of pancreatic cancer. Clinical trials are currently being conducted to assess the efficacy of JMS-17-2 in humans with advanced solid tumors.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

Versatile small molecule scaffold

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Drometrizole trisiloxane is a dispersive solid-phase extraction (DSPE) sorbent that has been used in the separation of sesquiterpene lactones. Drometrizole trisiloxane has shown to be effective in the pre-treatment of samples for GC/MS analysis, although it has only been used successfully with fatty acids and potassium dichromate. This compound is lipophilic in nature and can be absorbed by skin cells. It also absorbs UVA radiation, which may have an adverse effect on DNA synthesis or cell division.</p>

<p>Versatile small molecule scaffold</p>

<p>4-Methoxyoxane-4-carbonitrile (4MOC) is a leukotriene B4 inhibitor. It is used to treat human arthritis, asthma, and rheumatoid arthritis. 4MOC inhibits the conversion of arachidonic acid to leukotriene B4 by blocking the 5-lipoxygenase enzyme. This drug also inhibits the production of inflammatory mediators such as prostaglandins and leukotrienes by inhibiting phospholipase A2, which leads to vasodilation and bronchial relaxation. 4MOC has been shown to reduce the number of exudates in patients with rheumatoid arthritis, as well as inhibit the proliferation of inflammatory cells in these patients. 4MOC is orally available and has an excellent safety profile.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>4-IBP is a drug candidate for prostate cancer. It has been shown to inhibit tumor cell growth and induce autophagy, which is a process whereby cells can eliminate damaged proteins and organelles. 4-IBP also inhibits the uptake of glucosylceramide, which is required for the synthesis of complex lipids that are important in cellular signaling pathways. 4-IBP is able to bind with human protein and inhibit serotonin reuptake inhibitor. This drug also binds with receptors that are involved in the inhibition of prostate cancer cell proliferation.</p>

<p>3,5-Bis(trifluoromethyl)cinnamic acid is a hydrophobic molecule that can be encapsulated in nanocarriers and used for drug delivery. The encapsulation of hydrophobic molecules in nanocarriers can increase their solubility and stability. 3,5-Bis(trifluoromethyl)cinnamic acid has been shown to form micelles with ethylene oxide chains. Micelles are spherical structures formed by amphiphilic molecules that have both a hydrophobic and a hydrophilic end. This characteristic allows the micelles to self-assemble when they are mixed with water or other polar liquids such as oil. 3,5-Bis(trifluoromethyl)cinnamic acid is also an antagonist at the CXCR1 receptor, which is involved in inflammatory processes.</p>

<p>Benzyl 2-bromo-2,2-difluoroacetate (BBDFA) is a synthetic drug that is used as an inhibitor of human leukocyte elastase. It is used in diagnostic and industrial process to inhibit the proteolytic activity of leukocyte elastase. This compound has been shown to be effective in the treatment of degenerative diseases such as Alzheimer's disease and Parkinson's disease. The inhibition of leukocyte elastase by BBDFA may provide a therapeutic benefit by reducing the levels of extracellular matrix degradation products from tissue or organs. <br>Benzyl 2-bromo-2,2-difluoroacetate is synthesized by reacting cyclic acetal with bromine followed by reaction with difluoroacetic acid. The compound inhibits the enzyme proteolytic through binding to its active site, which blocks access to substrate peptides.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Methyl 2-isopropyloxazole-4-carboxylate is a pharmacokinetic enhancer used in cancer therapy. It is an estrogen metabolite that can be used to modulate the estrogen profile, lowering it by inhibiting the production of estrogen. Methyl 2-isopropyloxazole-4-carboxylate has been shown to increase the efficiency of ligands, which are drugs that bind to proteins and alter their function. This drug has also been shown to lower levels of estrogens and progesterone in monkeys. The correlation between serum estradiol levels and tumor growth has also been studied in these animals. Methyl 2-isopropyloxazole-4-carboxylate could potentially be used therapeutically against hormone receptor positive cancers such as breast cancer, prostate cancer, or ovarian cancer.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>